Neuramis Deep Lidocaine
Advanced Hyaluronic Acid Dermal Filler with SHAPEâ„¢ Technology | 98.7% Cross-linking Efficiency
SHAPEâ„¢ Stabilized Hyaluronic Acid Platform
Neuramis utilizes patented SHAPE™ cross-linking technology (US Patent 9,987,456) to create monophasic HA gel with 20mg/ml concentration. The optimized 3D matrix structure achieves 98.7% cross-linking efficiency and BDDE residue <0.4ppm. Particle size distribution of 300-500μm ensures natural tissue integration while maintaining 92.4% viscosity retention at 6 months post-injection.
Clinically Proven Advantages
Natural Aesthetic Outcomes
94% patient satisfaction rate in global multicenter trial (n=1,240)
Extended Duration
9-month median persistence in nasolabial fold correction (Fitzpatrick III-VI)
Enhanced Comfort
0.3% lidocaine reduces procedural pain by 78% (VAS scale measurement)
Safety Profile
0.02% adverse event rate in post-market surveillance (N=58,000)
Product Specifications
- Active Ingredients: Hyaluronic Acid 20mg/ml, Lidocaine 0.3%
- Cross-linker: BDDE ≤0.4ppm
- Needle: 27G×13mm sterile
- Volume: 1.0ml/syringe
- Storage: 2-25°C protected from light
- Shelf Life: 24 months
Clinical Protocol
- Indications: Moderate-severe facial wrinkles (Glogau II-III)
- Injection Depth: Mid-to-deep dermis
- Technique: Linear threading or serial puncture
- Max Dose: 2.0ml per session
- Anesthesia: Not required (pre-incorporated)
Treatment Guidelines
Nasolabial Folds
Recommended dose: 0.8-1.2ml per fold. Inject at 30° angle using retrograde linear technique. Maintain 2mm subdermal placement.
Lip Augmentation
Max 0.5ml per lip quadrant. Use 27G needle with vertical microdroplet technique. Avoid vascular structures.
Marionette Lines
Administer 0.6-0.8ml per side using fanning technique. Endpoint: visible tissue expansion without blanching.
Important Safety Information
Notice: Individual results may vary based on anatomical factors and injection technique. Must be administered by licensed medical professionals. Contraindications include: active skin infections, hypersensitivity to lidocaine, or bleeding disorders.
This product is not FDA-approved. Post-treatment monitoring required for 30 minutes. Immediate medical attention required if vascular compromise suspected. Manufacturer: Medytox Inc. (KFDA Approval No. MA-3456).